COMMUNIQUÉS West-GlobeNewswire

Ipsen lance un nouveau programme de rachat d’actions
18/05/2026
Ipsen lance un nouveau programme de rachat d’actions PARIS, FRANCE, 18 MAI 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui avoir confié à un prestataire de services d’investissement un mandat à l’effet de [...]
Ipsen initiates a new share buy-back program
18/05/2026
Ipsen initiates a new share buy-back program PARIS, FRANCE, 18 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it has appointed an investment services provider to purchase an aggregate number of up to [...]
NovalGen Appoints Dr Laurent Fischer as Chair of the Board
18/05/2026
LONDON, May 18, 2026 (GLOBE NEWSWIRE) -- NovalGen today announced the appointment of Dr Laurent Fischer, a globally recognized biopharmaceutical executive, as Non-Executive Chair of the Board of Directors with immediate [...]
AVITA Medical to Host Investor Webinar Briefing
18/05/2026
VALENCIA, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective [...]
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
17/05/2026
CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data [...]
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
17/05/2026
More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC alone Deep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12, 24 and 48 weeks [...]
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
17/05/2026
Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting PARIS and CAMBRIDGE, Mass., May 17, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ [...]
NANOBIOTIX ANNONCE LA PRÉSENTATION DE DONNÉES DE LA PREMIÉRE PARTIE DE L’ÉTUDE CLINIQUE RANDOMISÉE DE PHASE 2 EVALUANT JNJ-1900 (NBTXR3) DANS LES CANCERS DU POUMON DE STADE 3 INOPÉRABLE
17/05/2026
Données présentées par Johnson & Johnson lors de la réunion annuelle 2026 de la Société européenne d'oncologie radiothérapeutique (ESTRO) PARIS et CAMBRIDGE, Mass., 17 mai 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX ( [...]
Ipsen présente les derniers résultats d'une étude de phase II sur la corabotase, première de sa classe, concernant les rides glabellaires, montrant une durée d'effet prolongée et un niveau de satisfaction constamment élevé chez les patients
16/05/2026
Les patients traités avec la corabotase ont présenté un délai d'action rapide de 0,84 jour et un pic d'effet statistiquement supérieur à celui du placebo À la semaine 24, 60,8 % des patients traités avec la corabotase [...]
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
16/05/2026
Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo At Week 24, 60.8% of patients treated with corabotase experienced clinically significant [...]
ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026
16/05/2026
– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed Primary Response Evaluation (PRE) – – Updated durability data shows 85.7% (18/21) [...]
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
16/05/2026
The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement of 5.1 months in median PFS was observed for the high-dose fianlimab [...]
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
15/05/2026
Completed Formal Dispute Resolution Meeting with FDA regarding Complete Response Letter (CRL) for ONS-5010; Decision Expected This Month Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe with Commercial [...]
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
15/05/2026
CAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA ® ) platform to develop a new [...]
4DMT Announces New Employment Inducement Grants
15/05/2026
EMERYVILLE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
15/05/2026
- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen – - Appointed Alireza Javadi, Ph.D. as Chief Technical Officer - - Appointed Jesper [...]
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
15/05/2026
Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prostate cancer–specific [...]
Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
15/05/2026
HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central [...]
Solana Company Reports First Quarter 2026 Financial Results
15/05/2026
NEWTOWN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company, today announced results for the quarter ended March 31, 2026. First Quarter Recent [...]

Pages